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Abstract: The hydrazine and hydrazide derivatives of benzo-γ-pyrones with fluorine substituents
remain an unexplored group of chemical compounds. This preliminary study reports the synthesis,
structural assessment, initial microbiological screening and biological testing of the synthesized
compounds on cell lines using the XTT-assay. A series of 10 novel hydrazine and hydrazide
derivatives of 3-formylchromone were synthesized and their structures determined. Structural
assessment consisted of elemental analysis, IR, 1H-NMR, 13C-NMR, MS and crystallographic
studies. Antimicrobial activity was tested on standard strains representing different groups of
microorganisms. The tested compounds were found to inhibit microbial growth. Concentrations of
0.01–1250 µmol/L were found to influence cell proliferation, demonstrating antiproliferative and
stimulation of proliferation against two cell lines: the L929 cell line (mouse fibroblast cell line) and
the EA.hy926 cell line (the human umbilical vein, somatic cell hybrid).
Keywords: hydrazine; hydrazide; benzo-γ-pyrones; 3-formylchromone; XTT-assay; anti-proliferative
activity
1. Introduction
Due to the increasing problem of drug resistance, the search for novel and efficient antimicrobial
and antiproliferative agents is a worldwide concern. Benzopyrones occur widely in Nature,
and benzopyrone derivatives have been reported in algae [1], fungi [2,3] and plants [4,5] including
trees [6,7]. These compounds show broad pharmacological activities, and studies have found them to
have antimicrobial, antitumor, antioxidant, anti-HIV and antiallergenic properties [8–14]. They have
also been suggested as playing a potentially important role in the development of Alzheimer’s Disease
treatment [15].
3-Formylchromone is a benzopyrone derivative characterized by high chemical reactivity,
especially when nitrogen nucleophilic groups are present. Its structure includes three electron-deficient
sites (C–2, C–4, –CHO) where attack by strong nucleophilic agents results in the production of
various types of compounds [16]. However, no procedure resulting in the formation of hydrazine
and hydrazide derivatives of 3-formylchromone by spontaneous, internal rearrangement of the
benzo-γ-pyrone ring has been described [17–20]. Due to its many possible chemical modifications,
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the benzo-γ-pyrone structure offers a broad scope of possibilities for the search of the new
pharmaceuticals. Previous studies suggest that chemical synthesis of these new compounds is
possible [21].
The effects of fluorine substituents on the bioactivity of existing compounds may often be poorly
understood and unpredictable, but they are nevertheless significant [22]. Fluorinated drugs are used
for treatment of diseases of the central nervous system, cardiovascular diseases and obesity, as well as
in antibacterial and antifungal therapy [23]. The presence of a fluorine substituent in a molecule can
influence its conformation, pKa, intrinsic potency, membrane permeability, metabolic pathways and
pharmacokinetic properties [24]. Fluoride itself is mostly used as an anticaries agent on a daily basis.
It is known to have an important effect on the bacteria of dental plaque. Its action affects bacterial
metabolism as an enzyme inhibitor [25,26]. Hence the presence of a fluorine substituent can play a
major role on the usability of a compound as a novel treatment alternative.
Copper plays important metabolic role in living organisms. Copper action is observed in redox
chemistry of mitochondrial respiration and physiological stability maintenance by free radicals
elimination as well as iron absorption [27,28]. Raised or lowered levels or copper are found in many
diseases such as rheumatoid arthritis, gastrointestinal ulceration, epilepsy, diabetes and cancer [29].
Locally raised levels of copper are crucial for angiogenesis to occur [30].
Previous studies have confirmed the antiproliferative properties [12,31] and biochemical
activity [32,33] of 3-formylchromone derivatives. Moreover, biological activity of copper (II) complexes
of 3-formylchromone, was also described [21]; however, hydrazine and hydrazide derivatives of
benzopyrones with fluorine substituents remain a poorly-analyzed group of compounds. Therefore,
the present study describes the synthesis and subsequent analysis of compounds of this type, with the
aim of better understanding their potential biological properties.
The study presents the molecular and crystal structures of synthesized compounds. Initial
antimicrobial activity testing was done on standard strains representing different groups of
microorganisms. This study also investigates the influence on proliferation on two nonpathogenic cell
lines: L929 (mouse fibroblast cell line) and the human umbilical vein somatic cell hybrid EA.hy926.
2. Results and Discussion
2.1. Chemistry
3-Formylchromone was previously synthesized in the Department of Bioinorganic Chemistry,
Medical University of Lodz using the Vilsmeier-Haack reaction [34] with use of o-hydroxyacetophenone
and DMF/POCl3 acting as substrate and solvent, respectively. The synthesis of novel hydrazine
(compounds 1, 3, 4, 6, 7, 8, 9, 10) and hydrazide (compounds 5, 11) derivatives of benzo-γ-pyrones
with fluorine substituents by the condensation reaction with 3-formylchromone is shown in Scheme 1.
All reactions were carried out at reflux temperature because they did not proceed at room temperature.
The syntheses afford moderate yields (60–80%). The structures of all compounds were established and
confirmed by 1H-NMR, 13C-NMR, IR, MS and elemental analysis. All the compounds present similar
spectroscopic characteristics because of their structural similarity. In the IR spectra two groups are
considered to be present and characteristic for all ligands and complexes: 1620–1644 cm−1 (C=O) and
1517–1584 cm−1 (CH=N). Compounds 1, 3, 5, 8, 10 were synthesized in the form of crystals and for
them X-ray diffraction studies were performed.
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Scheme 1. Synthesis of hydrazine and hydrazide derivatives of 3-formylchromone. Reaction 
conditions: solvent: CH3COOC2H5, time: 48h, temperature: reflux temperature, crystallization from 
50:50 acetone/ethanol. Hydrazine derivatives of 3-formylchromone: 1: R2=R5=F, R3=R4=R6=H; 3: 
R4=CF3, R2=R3=R5=R6=H; 4: R3=R5=CF3, R2=R4=R6=H; 6: R2=R3=R5=R6=F, R4=H; 7: R2=CH3, R5=F, 
R3=R4=R6=H; 8: R2=R4=R6=F, R3=R5=H; 9: R2=R3=R4=R5=R6= F, 10: R2=CF3, R3=R4=R5=R6=H. 
2.2. X-ray Diffraction Studies 
The molecular structures of 1, 3, 5, 8, 10 with their atomic labeling and anisotropic displacement 
ellipsoids are depicted in Figure 1. Compounds 1 and 5 crystallize with two molecules in the 
asymmetric unit. Structure 5 crystallizes as a hydrate. All non-hydrogen atoms were refined 
anisotropically. The hydrogen atoms, except those attached to the nitrogen atom, H2A and H4A; and 
the hydrogen atoms of the water molecule, were geometrically fixed at calculated positions using a 
riding model. 
In 3, the fluorine atoms in the CF3 group were refined as disordered over two equally-occupied 
positions each, and their anisotropic displacement parameters (Uij) were restrained to be similar. 
Additionally, geometrical similarity constraints were applied to all C–F bond lengths by SADI 
instruction. 
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a riding model.
I , t e fl ri e t s i t e 3 gr ere refi e s is r ere er t e ll - cc ie
siti s each, and their anis tropic displacement parameters (Uij) were restrained to be
similar. Additionally, geometrical similarity constraints were applied to all C–F bond lengths by
SADI instruction.
In 10, two carbon atoms from the heterocyclic ring (C2 and C3) were found to be disordered
and refined with two alternative positions with the final site-occupancy factors A to B components:
kA:kB = 0.856 (5):0.144 (5). Crystallographic data and the final figures of merit for structure refinements
are summarized in Table 1.
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Figure 1. Molecular structures of crystal compounds with anisotropic displacement ellipsoids drawn 
at the 50% (1, 8, 10) and 30% (3, 5) probability level with atomiC-Numbering scheme. Hydrogen 
atoms are shown as spheres of arbitrary radius. For clarity, only three from six fluorine atoms (F1, F2, 
F3) with occupancy factor equal to 0.5 are shown for structure 3. For structure 10, the carbon atoms 
with higher site occupancy factors are shown. 
In 10, two carbon atoms from the heterocyclic ring (C2 and C3) were found to be disordered and 
refined with two alternative positions with the final site-occupancy factors A to B components: kA:kB 
= 0.856 (5):0.144 (5). Crystallographic data and the final figures of merit for structure refinements are 
summarized in Table 1. 
Table 1. Crystallographic data for 1, 3, 5, 8 and 10. 
 1 3 5 8 10 
Empirical formula C16H10F2N2O2 C17H11F3N2O2 C34H22F2N4O6 H2O C16H9F3N2O2 C34H22F6N4O4 
Formula weight 300.26 332.28 638.57 318.25 664.55 
Crystal system Triclinic Monoclinic Monoclinic Triclinic monoclinic 
Space group Pī P21/c P21/n Pī C2/c 
a (Å) 6.8791 (2) 16.8965 (9) 11.1731 (10) 3.9211 (1) 25.5373 (11) 
b (Å) 12.0848 (4) 4.8728 (2) 16.4967 (12) 11.7020 (2) 7.4105 (3) 
c (Å) 16.1485 (6) 18.4032 (10) 16.4583 (12) 14.2192 (3) 14.7383 (5) 
α (°) 94.432 (3) 90 90 88.791 (2) 90 
β (°) 100.817 (3) 105.343 (5) 109.125 (9) 87.938 (2) 93.014 (3) 
γ (°) 103.431 (3) 90 90 87.939(2) 90 
V (Å3) 1272.24 (8) 1461.19 (13) 2866.1 (4) 651.47 (2) 2785.28 (19) 
Z 4 4 4 2 4 
T (K) 100 (1) 290 (1) 293 (1) 100 (1) 91 (1) 
F (000) 616 680 1320 324 1360 
Dx (g cm−3) 1.568 1.510 1.480 1.622 1.585 
µ (mm−1) 0.125 0.126 0.114 0.138 0.132 
Wavelength (Å) 0.71073 0.71073 0.71073 0.71073 0.71073 
θ range (°) 3.11–30.0 3.75–30.0 3.13–30.0 3.32–30.0 3.12–30.0 
Measured reflections 14, 205 18, 926 30, 676 8452 14, 914 
Unique reflections 7388 4247 8335 3806 4067 
Figure 1. Molecular structures of crystal compounds with anisotropic displacement ellipsoids drawn
at the 50% (1, 8, 10) and 30% (3, 5) probability level with atomiC-Numbering scheme. Hydrogen atoms
are shown as spheres of arbitrary radius. For clarity, only three from six fluorine atoms (F1, F2, F3) with
occupancy factor equal to 0.5 are shown for structure 3. For structure 10, the carbon atoms with higher
site occupancy factors are shown.
Table 1. Crystallographic data for 1, 3, 5, 8 and 10.
1 3 5 8 10
Empirical formula C16H10F2N2O2 C17H11F3N2O2 C34H22F2N4O6 H2O C16H9F3N2O2 C34H22F6N4O4
Formula weight 300.26 332.28 638.57 318.25 664.55
Crystal system Triclinic Monoclinic Monoclinic Triclinic monoclinic
Space group Pı¯ P21/c P21/n Pı¯ C2/c
a (Å) 6.8791 (2) 16.8965 (9) 11.1731 (10) 3.9211 (1) 25.5373 (11)
b (Å) 12.0848 (4) 4.8728 (2) 16.4967 (12) 11.7020 (2) 7.4105 (3)
c (Å) 16.1485 (6) 18.4032 (10) 16.4583 (12) 14.2192 (3) 14.7383 (5)
α (◦) 94.432 (3) 90 90 88.791 (2) 90
β (◦) 100.817 (3) 105.343 (5) 109.125 (9) 87.938 (2) 93.014 (3)
γ (◦) 103.431 (3) 90 90 87.939(2) 90
V (Å3) 1272.24 (8) 1461.19 (13) 2866.1 (4) 651.47 (2) 2785.28 (19)
Z 4 4 2
T (K) 100 (1) 290 ( ) 293 (1) 100 (1) 91 (1)
F (000) 616 680 1320 324 1360
Dx (g cm−3) 1.568 1.510 1.480 1.622 1.585
µ (mm−1) 0.125 0.126 0.114 0.138 0.132
Wavelength (Å) 0.71073 0.71073 0.71073 0.71073 0.71073
θ range (◦) 3.11–30.0 3.75–30.0 3.13–30.0 3.32–30.0 3.12–30.0
Measured reflections 14, 205 18, 926 30, 676 8452 14, 914
Unique reflections 7388 4247 8335 3806 4067
Observed reflections [I > 2σ (I)] 5176 2004 3518 3359 2917
Completeness to θmax (%) 99.5 99.8 99.8 99.7 99.8
Parameters/restraints 405/0 249/93 4 1/0 212/0 244/0
R [I > 2σ (I)] 0.0481 .0696 0.0607 0.0336 0.0518
wR (all data) 0.1372 0.2536 0.1905 0.1016 0.1434
S 1.006 1.030 1.011 1.062 1.058
∆ρmax (e Å−3) 0.494 0.299 0.216 0.443 0.561
∆ρmin (e Å−3) −0.278 −0.365 −0.214 −0.194 −0.490
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The examined molecules consist of a 4H-chromene-4-one system (a heterocyclic ring fused
with a benzene ring) substituted at position 3 by a phenylhydrazonomethyl group, with a
methylene-benzohydrazide group being present in structure 5. In all structures, the hydrazine moiety
is oriented similarly with respect to the chromone ring. The structures differ from each other in fluorine
substituents. 1 and 8 differ only in the number of fluorine atoms substituted at the phenyl ring: two
and three atoms, respectively. Both crystallize in a triclinic system, in the Pı¯ space group; however,
two independent molecules were identified in an asymmetric unit for compound 1. Compound 5
also crystallizes with two molecules in an asymmetric unit, but only one fluorine atom is attached
to the terminal phenyl ring at the para position to the hydrazide group. The trifluoromethyl group
is characteristic of structures 3 and 10, which are substituted at positions 4 and 2 of the terminal
phenyl group, respectively. Selected geometrical parameters are listed in Table S1 (see Supplementary
Materials). The bond lengths and valence angles of the studied structures are generally similar;
however, the bonds in 3 and 5 seem to be slightly shorter, probably due to the X-ray measurement
at room temperature. On the other hand, in 10, the disorder of two carbon atoms, C2 and C3, within
the heterocyclic ring results in greater discrepancies in the geometrical parameters observed within
the disordered region in comparison to the other compounds. In contrast to bond lengths and angles,
some torsion angles differ quite significantly, indicating changes in the molecular conformations of
examined structures. The heterocyclic ring is planar, and together with a flat benzene ring, forms a
chromone ring, which can be also considered as substantially planar. In seven molecules analyzed,
the total puckering amplitude (Q) for the 10-membered ring was found to range from 0.028 (2) Å
to 0.069 (3) Å [35], for 5 (molecule B) and 5 (molecule A), respectively. Furthermore, the maximum
deviation of carbon atom C4 from the best plane of chromone moiety is 0.045 (2) Å, observed in
5 (molecule A).
The spatial arrangement of two planar fragments, i.e., the 10-membered chromone ring and the
terminal phenyl group, is shown in Figure 2. Superimposing the structures of the seven considered
molecules, it can be seen that the dihedral angle between the best planes of the chromone and phenyl
rings differ quite significantly from 2.96 (6)◦ in 10 (indicated in orange in Figure 2) to 25.88 (3)◦ in
8 (indicated in red in Figure 2). Since compound 5 has an additional carbonyl group between the
hydrazine and phenyl fragments, its independent molecules (cyan and blue in Figure 2) demonstrate
conformations which are considerably different to other derivatives, and even to each other. In 5
two independent molecules differ mostly within carbonyl group and attached phenyl ring, thus the
dihedral angle between the best planes of terminal phenyl ring and the 10-membered ring is 12.48 (10)◦
and 7.82 (10)◦ for molecules A and B, respectively. For comparison, in 1 the corresponding dihedral
angle is 12.75 (6)◦ and 4.68 (6)◦, for molecules A and B, respectively.
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olecule A of 5 (cyan), olecule B of 5 (blue), 8 (red) and 10 (orange).
The similarities and differences in the molecular structures of the studied compounds are reflected
in their crystal packing arrangements, as illustrated in Figure 3. Table 2 lists some important hydrogen
bonding geometries in the analyzed structures.
Molecules 2018, 23, 2067 6 of 16
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Structure 8, a related structure, exhibits quite similar packing; however, its higher monoclinic 
symmetry and the presence of only one independent molecule in the asymmetric unit result in 
remarkable differences being seen in respect to structure 1.  
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Table 2. Hydrogen-bonding geometries (Å,◦) for 1, 3, 5, 8 and 10.
Comp. H–Bond D–H H···A D···A D–H···A
1
N2–H2A···F4 0.90 (2) 2.45 (2) 2.937 (2) 114 (2)
N2–H2A···O4i 0.90 (2) 2.28 (2) 3.091 (2) 150 (2)
N4–H4A···O2i 0.86 (2) 2.15 (2) 2.957 (2) 158 (2)
3 N2–H2A···O2i 0.91 (3) 2.00 (3) 2.903 (3) 172 (2)
5
N2–H2A···O6i 0.83 (2) 2.11 (2) 2.910 (2) 163 (2)
N4–H4A···O7 0.90 (2) 1.91 (3) 2.785 (2) 162 (2)
O7–H7A···O3 0.95 (3) 1.83 (3) 2.750 (2) 162 (2)
O7−H7A···N1 0.95 (3) 2.50 (3) 3.143 (2) 125 (2)
O7–H7B···O6ii 0.87 (4) 2.17 (4) 2.929 (3) 145 (3)
O7–H7B···N3ii 0.87 (4) 2.42 (4) 3.061 (3) 131 (3)
8 N2–H2A···O2i 0.85 (2) 2.10 (2) 2.926 (1) 163 (2)
10
N2–H2A···O2i 0.90 (2) 2.32 (2) 3.150 (2) 154 (2)
N2–H2A···F1 0.90 (2) 2.27 (2) 2.849 (2) 122 (2)
Symmetry codes: 1 (i) 1−x, 2−y, 1−z; 3 (i) −x+1, −y+2, −z+1; 5 (i) −1+x, y, z; (ii) 1−x, −y, 1−z; 8 (i) 1−x, 1−y, 1−z;
10 (i) 1−x, y, 12−z.
In 1, symmetrically-related molecules A and B form dimers through two N–H···O hydrogen
bonds; there is no pseudo-symmetry between monomers. Rather weak N2–H2A···F4 interactions
(observed between independent molecules) links dimers in a tetramer (Figure 3a). The inversion
centers enable stacking pi···pi interactions. The molecular stacks are built from molecules that are
centrosymmetrically oriented along the crystallographic a direction, each stack being composed of one
type of independent molecules A and B, respectively.
Structure 8, a related structure, exhibits quite similar packing; however, its higher monoclinic
symmetry and the presence of only one independent molecule in the asymmetric unit result in
remarkable differences being seen in respect to structure 1.
Figure 3 shows the centrosymmetric dimers and their arrangement in the crystal lattice. It can be
seen that the molecular conformation of 8 differs significantly from two molecules of 1 (Figure 3a or
Figure 3d), thus justifying changes in lattice symmetries and the number of independent molecules in
the asymmetric unit.
Centrosymmetric dimers, a characteristic hydrogen-bonded motif, are also found in 3 and 10. The
position of the trifluoromethyl group influences the mutual arrangement of molecules in dimers. The
molecules in dimers of 3 (Figure 3b) are almost coplanarly oriented, in contrast to the tightly twisted
molecules in dimers of 10, where the dihedral angle between corresponding chromone rings in dimers
is 52 (1)◦ (Figure 3e).
Since 5 exceptionally crystallizes as hydrate, and its molecular structure demonstrates remarkable
differences to those of other analyzed derivatives, it possesses a completely different setup of
intermolecular interactions (Table 2, Figure 3c). The molecules are organized to form infinite
hydrogen-bonded chains. Figure 3c demonstrates that chain motifs are propagated along the
[100] direction.
Furthermore, X-ray crystal determinations have revealed the presence of aromatic pi···pi
interactions in four of the five crystal structures investigated. Unexpectedly, in 3, although most planar
hydrogen-bonded dimers are formed with almost linear N–H···O interaction between interacting
molecules, no stacking interactions are observed. In Figure 3b, it can be clearly seen that the
arrangement of dimers it is not conductive to creating pi···pi stacks. In all structures apart from 3,
the distance between ring centroids Cg···Cg ranges from 3.415 (1) Å to 3.921 (1) Å, and the interplanar
spacing from 3.269 (1) Å to 3.552 (1) Å. Depending on the structure, different aromatic rings interact
with each other (see Table S2 in Supplementary Materials).
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2.3. Initial Determining the Sensitivity of Microorganisms to the Obtained Chemical Compounds
Fifteen strains of microorganisms from different species were used. The growth inhibition
zones were evaluated in two independent experiments (n = 2 in each of them), and the potential
inhibitors of microbial growth are presented in Table 3. The hydrazine and hydrazide derivatives
of 3-formylchromone constitute a class of potential antimicrobial agents and are worthy of further
investigation. 1, 4, 7, 10, 11 exhibit antimicrobial potential at concentrations of 100, 200 µg/mL or
at both used concentrations. In case of N. meningitidis (result with *) the action of 9 was noted just
for 100 µg/mL and the influence in concentration of 200 µg/mL was not observed. The rest of the
tested compounds (3, 5, 6, 8) were not able to inhibit microbial growth during the experiment and only
positive results were presented in Table 3.
Table 3. Inhibition of growth zones (lowest effective studied concentration).
Strain 1 4 7 9 10 11
S. epidermidis 100 µg/mL 100 µg/mL 100 µg/mL 100 µg/mL
S. pneumoniae 100 µg/mL
S. pyogenes 200 µg/mL
S. aureus 100 µg/mL
N. meningitidis 100 µg/mL *
* N. meningitidis, the action of 9 was noted just for 100 µg/mL and the influence in concentration of 200 µg/mL was
not observed.
2.4. Cell Proliferation Study
Four independent experiments (n = 4 for each used concentration) were performed.
Cell proliferation study results are presented in Table 4. With regard to their effect on the proliferation
of cell lines L929 and EA.hy926, it was found that the IC50 values tended to be lower for the EA.hy926
line, except for compound 7 and cisplatin. This indicates good or very good (in the case of 1, 3, 5, 8,
11) selectivity of action. The anti-proliferative properties of the studied compounds increased with
their concentration. Clear anti-proliferative properties were noted for 5, 8 and 11, which demonstrated
better performance than cisplatin on both lines (apart from 8 for L929), whereas 1 had such action
on EA.hy926 line. Complex 11 was found to have more clearly marked antiproliferative properties
than ligand 5, with its IC50 value being 46.89% lower for the L929 and 77.78% lower for EA.hy926.
Compounds 1 and 4, also demonstrated a weak stimulating effect on the proliferation of both cell lines,
while compounds 3 and 7 slightly stimulated the proliferation of the EA.hy926 line. Due to the dual
action of these compounds, it would be advisable to study their effect on stimulation of proliferation
at concentrations below 0.01 µmol/L. This dual action may be desirable during therapy, because the
dosage may affect the nature of the compounds.
Table 4. Cell proliferation study results.
Compound
IC50 [µmol/L] The Range of Influence [%, Control = 100%]
L929 EA.hy926 L929 EA.hy926
Cisplatin 74.44 67.36 8.49–55.70 8.71–75.14
1 208.51 59.15 27.64–101.8 14.79–106.26
3 3714.50 975.09 55.91–96.98 37.40–101.33
4 1034.69 533.79 45.61–101.31 28.46–102.18
5 65.92 0.18 16.03–56.35 11.81–60.64
6 727.78 578.25 40.05–93.11 24.47–97.86
7 953.76 953.37 44.89–96.11 42.43–101.05
8 98.49 18.12 38.11–64.40 23.31–63.94
9 385.65 253.00 13.92–85.11 13.15–69.88
10 1207.48 645.48 48.62–73.47 31.21–94.69
11 35.01 0.04 10.30–75.02 8.58–53.23
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2.5. Statistical Analysis of Cell Proliferation Results
It was impossible to test the statistical normality in the case of 11 (EA.hy926) at 1250 and 500 µM
due to n = 4 = const. (A = 4 × 0.092 and 4 × 0.069 for 1250 and 500 µM, respectively). At 250 µM,
A = 0.066 and 3 × 0.064 were obtained, resulting in p = 0.00124 (Shapiro-Wilk test). For 10 (L929) at
0.01 µM, A = 0.061, 0.304, 0.308 and 0.334 were obtained, resulting in p = 0.05104 (t-test) and 0.02780
(Shapiro-Wilk test).
The rest results of the t-test of the cell proliferation study showed that it was not necessary to
discard H0, because of p ≤ 0.01904. The Shapiro-Wilk test found that the following samples met the
normal distribution criteria, except: 1 (L929) at 1000 and 750 µM (p = 0.00683 and 0.01373, respectively),
1 (EA.hy926) at 250 µM (p = 0.01353), 3 (EA.hy926) at 500 and 100 µM (p = 0.01684 and 0.00680,
respectively), 4 (L929) at Control and 500 µM (p = 0.01488 and 0.01513, respectively), 4 (EA.hy926) at
0.1 µM (p = 0.01724), 5 (L929) at 1250 µM (p = 0.01662), 5 (EA.hy926) at 1 µM (p = 0.01843), 6 (L929) at
1250 µM (p = 0.01873), 8 (L929) at 0.1 µM (p = 0.01476), 8 (EA.hy926) at 1 µM (p = 0.02419), 9 (EA.hy926)
at 500 µM (p = 0.02386), 10 (EA.hy926) at 0.01 µM (p = 0.01926). The described incompatibilities were
caused by the presence of one outlier result in the series of four experiments.
3. Experimental Section
3.1. General Information
All hydrazines and hydrazides used for synthesis were purchased from Sigma-Aldrich (Poznan,
Poland) and Alfa Aesar (Karlsruhe, Germany) and used without additional purification. Melting
points were determined with a use of HMK 73/4521 apparatus (VEB Analytik, Dresden, Germany).
The 1H-NMR spectra were recorded using an Avance III 600 MHz spectrometer (Bruker, Billerica, MA,
USA) with DMSO-d6 as solvent (measurement frequency: 600 MHz). The 13C-NMR spectra were
recorded using a Avance III 600 MHz spectrometer (Bruker) with use of DMSO-d6 (measurement
frequency: 150 MHz). IR spectra were recorded using an ATI Mattson Infinity Series FTIR (ATI,
Markham, ON, Canada) in KBr. Elemental analysis were performed with a Perkin Elmer 2400 analyzer
(Waltham, MA, USA). The mass spectra were recorded using a Synapt G2-Si spectrometer (Waters,
Warsaw, Poland) equipped with an electrospray source. ESI-MS spectra were registered in a positive
ion mode. The sample was pre-dissolved in 100 µL of THF and then added to 900 µL of methanol.
3.2. Synthesis of Hydrazine and Hydrazide Derivatives of 3-Formylchromone
3-Formylchromone (50 mg, 0.287 mmol) was dissolved in ethyl acetate (30 mL) at room
temperature. The temperature was raised to reflux temperature and mixture was stirred until the
3-formylchromone was fully dissolved. After 5 min, a suitable amount (1 molar equivalent) of
substituted aromatic hydrazine or hydrazide was slowly added (dissolved just before addition in ethyl
acetate). Substances were mixed and heated under reflux for 48 h. The obtained precipitates were
filtered and air-dried. Resulting substances was recrystallized from 50:50 acetone/ethanol.
3.3. Synthesis of Cu(II) 3-Formylchromone Hydrazide Complex
4-Fluorobenzoic acid [1-(4-oxo-4H-chromen-3-yl)-meth-(E)-ylidene]-hydrazide (50 mg,
0.161 mmol) was dissolved in ethyl acetate (30 mL). The temperature was raised to reflux temperature
and mixture was stirred until dissolved. After 5 min, a suitable amount (1 molar equivalent)
of anhydrous CuCl2 was added. The substances were mixed and heated under reflux for 48 h.
The obtained precipitate was filtered and air-dried. The resulting substance was recrystallized from
50:50 acetone/ethanol.
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3.4. Spectral and Elemental Analysis
3-[(2,5-Difluorophenyl)-hydrazonomethyl]-chromen-4-one (1). Yellow solid. Yield: 68%. m.p. 226–227 ◦C.
Anal. calcd. for C16H10F2N2O2: C, 64.00; H, 3.36; N, 9.33. Found: C, 63.95; H, 2.93; N, 9.36%. FT IR
(KBr, cm−1) νmax: 3271.86 (NH2), 1628.54 (C=O), 1582.35 (CH=N), 1290.34 (C-O). 1H-NMR δ: 10.60 (s,
1H, NH), 8.97 (s, 1H, -CH=), 8.30 (s, 1H, H-2, chromone ring), 8.14–8.15 (dd, J = 1.9 and 8.1 Hz, 1H, H-5,
chromone ring), 7.84–7.87 (m, 1H, H-7, chromone ring), 7.73–7.74 (d, J = 8.3 Hz, 1H, H-8, chromone
ring), 7.54–7.57 (m, 1H, H-6, chromone ring), 7.34–7.37 (m, 1H, H-3, phenyl), 7.16–7.20 (m, 1H, H-6,
phenyl), 6.53–6.57 (m, 1H, H-4, phenyl). 13C-NMR δ: 175.4 (C=O), 160.6 (Ar-CF), 159.0 (Cq), 156.2 (CH),
154.0 (Ar-CF), 146.5 (CH), 144.9 (Ar-Cq), 134.8 (=CH-), 132.9 (CH), 126.3 (Cq), 125.7 (CH), 123.8 (CH),
119.4 (Cq), 116.4 (Ar-CH), 104.4 (Ar-CH), 101.2 (Ar-CH). HRMS (ESI) m/z calcd. for C16H11F2N2O2
(M + H)+: 301.0789, found 301.0792.
3-[(4-Trifluoromethylphenyl)-hydrazonomethyl]-chromen-4-one (3). Yellow solid. Yield: 76%. m.p.
215–216 ◦C. Anal. calcd. for C17H11F3N2O2: C, 61.45; H, 3.34; N, 8.43. Found: C, 61.02; H, 2.88;
N, 8.43%. FT IR (KBr, cm−1) νmax: 3271.86 (NH2), 1628.54 (C=O), 1582.35 (CH=N), 1290.34 (C-O).
1H-NMR δ: 10.91 (s, 1H, NH), 8.89 (s, 1H, -CH=), 8.15–8.16 (dd, J = 1.5 and 7.9 Hz, 1H, H-5, chromone
ring), 8.09 (s, 1H, H-2, chromone ring) 7.85–7.88, (m, 1H, H-7, chromone ring), 7.73–7.74 (d, J = 8.6 Hz,
1H, H-8, chromone ring), 7.55–7.57 (m, 3H, H-6, chromone ring, H-2, H-6, phenyl), 7.20–7.22 (d,
J = 8.7 Hz, 2H, H-3, phenyl; H-5, phenyl). 13C-NMR δ: 199.4 (-CF3), 175.4 (C=O), 160.4 (Ar-Cq), 160.2
(Ar-Cq), 159.8 (Ar-CH), 159.4 (Cq), 156.2 (CH), 153.5 (Ar-CH), 134.9 (=CH-), 131.2 (CH), 126.6 (Cq), 125.7
(CH), 123.7 (CH), 119.6 (Cq), 119.1 (CH), 112.2 (Ar-CH). HRMS (ESI) m/z calcd. for C17H12F3N2O2
(M + H)+: 333.0851, found 333.0858.
3-[(3,5-Bis-trifluoromethylphenyl)-hydrazonomethyl]-chromen-4-one (4). Light yellow solid. Yield: 60%.
m.p. 253–254 ◦C. Anal. calcd. for C18H10F6N2O2: C, 51.01; H, 2.52; N. 7.00. Found: C, 51.84; H, 1.98;
N, 7.07%. FT IR (KBr, cm−1) νmax: 3260.17 (NH2), 1640.84 (C=O), 1579.82 (CH=N), 1285.36 (C-O).
1H-NMR δ: 11.11 (s, 1H, NH), 9.03 (s, 1H, -CH=), 8.14–8.16 (dd, J = 1.5 and 7.9 Hz, 1H, H-5, chromone
ring), 8.10 (s, 1H, H-2, chromone ring), 7.85–7.88 (m, 1H, H-7, chromone ring), 7.73–7.75 (d, J = 8.3 Hz,
1H, H-8, chromone ring), 7.59 (s, 1H, H-6, chromone ring), 7.55–7.56 (m, 2H, H-2, H-6, phenyl), 7.35 (s,
1H, H-4, phenyl). 13C-NMR δ: 198.7 (-CF3), 192.6 (-CF3), 175.0 (C=O), 166.0 (Ar-Cq), 154.5 (CH), 138.8,
135.0 (=CH-), 131.8 (CH), 126.4 (Cq), 125.7 (CH), 123.8 (CH), 119.5 (Cq), 119.2 (CH), 112.1 (CH), 104.8,
(Ar-CH), 100.9 (Ar-CH). HRMS (ESI) m/z calcd. for C18H11F6N2O2 (M + H)+: 401.0725, found 401.0730.
4-Fluorobenzoic acid [1-(4-oxo-4H-chromen-3-yl)-meth-(E)-ylidene]-hydrazide (5). Yellow solid. Yield: 65%.
m.p. 201–202 ◦C. Anal. calcd. for C17H11FN2O3: C, 65.81; H, 3.57; N, 9.03. Found: C, 65.45; H, 3.51; N,
8.87%. FT IR (KBr, cm−1) νmax: 1642.11 (C=O), 1562.88 (CH=N), 1290.94 (C-O). 1H-NMR δ: 11.96 (s,
1H, NH), 8.85 (s, 1H, -CH=), 8.65 (s, 1H, H-2, chromone ring), 8.15–8.16 (dd, J = 1.1 and 7.9 Hz, 1H,
H-5, chromone ring), 8.02–8.04 (dd, J = 5.6 and 8.3 Hz, 2H, H-2, H-6, phenyl), 7.87–7.90 (m, 1H, H-7,
chromone ring), 7.74–7.76 (d, J = 8.2 Hz, 1H, H-8, chromone ring), 7.56–7.59 (t, 1H, H-6, chromone
ring), 7.37–7.34 (t, 2H, H-3, H-5, phenyl). 13C-NMR δ: 175.5 (C=O), 165.5 (Ar-CF), 163.9 (C=O), 162.4
(Cq), 156.3 (CH), 155.0 (Ar-CH), 141.0 (Ar-CH), 135.2 (=CH-), 130.9 (CH), 130.1 (CH), 126.6 (Cq), 125.7
(CH), 123.8 (CH), 119.2 (Cq), 118.8 (CH), 116.0 (Ar-CH), 115.9 (Ar-CH). HRMS (ESI) m/z calcd. for
C17H12FN2O3 (M + H)+: 311.0840, found 311.0832.
3-[(2,3,5,6-Tetrafluorophenyl)-hydrazonomethyl]-chromen-4-one (6). White solid. Yield: 72%. m.p.
241–242 ◦C. Anal. calcd. for C16H8F4N2O2: C, 57.15; H, 2.40; N, 8.33. Found: C, 56.94 H, 2.12;
N, 8.07%. FT IR (KBr, cm−1) νmax: 3243.32 (NH2), 1641.28 (C=O), 1517.95 (CH=N), 1226.21 (C-O).
1H-NMR δ: 10.58 (s, 1H, NH), 8.63 (s, 1H, -CH=), 8.31 (s, 1H, H-2, chromone ring), 8.14–8.15 (dd,
J = 1.5 and 7.9 Hz, 1H, H-5, chromone ring), 7.85–7.88 (m, 1H, H-7, chromone ring), 7.71–7.73 (d,
J = 7.9 Hz, 1H, H-8, chromone ring), 7.54–7.57 (m, 1H, H-6, chromone ring), 7.24–7.29 (m, 1H, H-4,
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phenyl). 13C-NMR δ: 175.4 (C=O), 156.3 (CH), 153.4 (Ar-CF), 135.0 (Ar-CF), 134.8 (=CH-), 126.4 (Cq),
125.7 (CH), 123.8 (CH), 119.4 (Cq), 119.1 (CH), 96.3 (Ar-CH). HRMS (ESI) m/z calcd. for C16H9F4N2O2
(M + H)+: 337.0600, found 337.0604.
3-[(5-Fluoro-2-methylphenyl)-hydrazonomethyl]-chromen-4-one (7). White solid. Yield: 80%. m.p.
224–225 ◦C. Anal. calcd. for C17H13FN2O2: C, 68.91; H, 4.42; N, 9.45. Found: C, 69.01; H, 4.19; N,
9.12%. IR (KBr, cm−1) νmax: 3312.09 (NH2), 1639.40 (C=O), 1537.14 (CH=N), 1281.08 (C-O). 1H-NMR
δ: 9.88 (s, 1H, NH), 8.93 (s, 1H, -CH=), 8.34 (s, 1H, H-2, chromone ring), 8.15–8.16 (dd, J = 1.5 and
7.9 Hz, 1H, H-5, chromone ring), 7.84–7.86 (m, 1H, H-7, chromone ring), 7.72–7.74 (d, J = 8.3 Hz, 1H,
H-8, chromone ring), 7.54–7.56 (t, 1H, H-6, chromone ring), 7.23–7.25 (dd, J = 2.6 and 11.7 Hz, 1H, H-6,
phenyl), 7.04–7.07 (t, 1H, H-3, phenyl), 6.47–6.50 (m, 1H, H-4, phenyl), 2.19 (s, 3H, CH3). 13C-NMR δ:
175.5 (C=O), 161.6 (Ar-CF), 156.3 (Cq), 153.5 (Ar-Cq), 145.0 (Ar-Cq), 134.8 (=CH-), 131.8 (CH), 131.6
(CH), 126.2 (Cq), 125.7 (CH), 123.8 (CH), 119.9 (Cq), 119.1 (CH), 116.9 (Ar-CH), 105.1 (Ar-CH), 95.4
(Ar-CH), 17.3 (-CH3). HRMS (ESI) m/z calcd. for C17H14FN2O2 (M + H)+: 297.1047, found 297.1039.
3-[(2,4,6-Trifluorophenyl)-hydrazonomethyl]-chromen-4-one (8). Dark yellow solid. Yield: 64%. m.p.
211–212 ◦C. Anal. calcd. for C16H9F3N2O2: C, 60.38; H, 2.85; N, 8.80. Found: C, 60.65; H, 2.52; N, 8.59%.
FT IR (KBr, cm−1) νmax: 3247.92 (NH2), 1644.23 (C=O), 1536.56 (CH=N), 1223.66 (C-O). 1H-NMR δ:
9.77 (s, 1H, NH), 8.58 (s, 1H, -CH=), 8.12–8.14 (dd, J = 1.5 and 7.9 Hz, 1H, H-5, chromone ring), 8.10
(s, 1H, H-2, chromone ring), 7.83–7.86 (m, 1H, H-7, chromone ring), 7.69–7.70 (d, J = 8.3 Hz, 1H, H-8,
chromone ring), 7.53–7.55 (m, 1H, H-6, chromone ring), 7.19–7.24 (m, 2H, H-3, H-5, phenyl). 13C-NMR
δ: 175.4 (C=O), 164.0 (Ar-CF), 156.1 (Ar-CF), 135.7 (=CH-), 127.2 (Cq), 125.8 (Cq), 125.2 (CH), 120.5
(Cq), 119.4 (CH). HRMS (ESI) m/z calcd. for C16H10F3N2O2 (M + H)+: 319.0694, found 319.0707.
3-(Pentafluorophenyl-hydrazonomethyl)-chromen-4-one (9). Yellow solid. Yield: 70%. m.p. 245–246 ◦C.
Anal. calcd. for C16H7F5N2O2: C, 54.25; H, 1.99; N, 7.91. Found: C, 54.43; H, 2.05; N, 7.85%. FT IR (KBr,
cm−1) νmax: 3271.30 (NH2), 1620.34 (C=O), 1524.56 (CH=N), 1272.51 (C-O). 1H-NMR δ: 10.41 (s, 1H,
NH), 8.61 (s, 1H, -CH=), 8.28 (s, 1H, H-2, chromone ring), 8.13–8.15 (dd, J = 1.9 and 8.1 Hz, 1H, H-5,
chromone ring), 7.84–7.87 (m, 1H, H-7, chromone ring), 7.70–7.72 (d, J = 8.7 Hz, 1H, H-8, chromone
ring), 7.54–7.56 (m, 1H, H-6, chromone ring). 13C-NMR δ: 175.4 (C=O), 156.3 (CH), 153.3 (Ar-CH),
135.0 (=CH-), 134.8 (CH), 126.4 (Cq), 125.7 (CH), 123.8 (CH), 119.3 (Cq), 119.2 (CH). HRMS (ESI) m/z
calcd. for C16H8F5N2O2 (M + H)+: 355.0506, found 355.0513.
3-[(2-Trifluoromethylphenyl)-hydrazonomethyl]-chromen-4-one (10). Yellow solid. Yield: 75%. m.p.
233–235 ◦C. Anal. calcd. for C17H11F3N2O2: C, 61.45; H, 3.34, N, 8.43. Found: C 61.23; H, 3.15;
N, 8.55%. FT IR (KBr, cm−1) νmax: 3319.96 (NH2), 1641.56 (C=O), 1584.02 (CH=N), 1274.36 (C-O).
1H-NMR δ: 9.98 (s, 1H, NH), 8.88 (s, 1H, -CH=), 8.51 (s, 1H, H-2, chromone ring), 8.15–8.17 (dd, J = 1.5
and 7.9 Hz, 1H, H-5, chromone ring), 7.84–7.86 (m, 1H, H-7, chromone ring), 7.83–7.82 (d, J = 8.2 Hz,
1H, H-8, chromone ring), 7.72–7.74 (m, 1H, H-6, chromone ring), 7.53–7.57 (m, 3H, H-3, H-5, H-6,
phenyl), 6.95–6.96 (m, 1H, H-4, phenyl). 13C-NMR δ: 188.8 (-CF3), 175.5 (C=O), 159.6 (Ar-Cq), 156.2
(CH), 153.8 (Ar-Cq), 142.8 (CH), 137.8 (Ar-CH), 134.9 (=CH-), 133.8 (CH), 126.3 (Cq), 125.7 (CH), 124.0
(CH), 122.5 (Cq), 119.3 (Cq), 119.1 (CH), 115.7 (Ar-CH), 111.9 (Ar-CH). HRMS (ESI) m/z calcd. for
C17H12F3N2O2 (M + H)+: 333.0851, found 333.0858.
Complex of 4-Fluorobenzoic acid [1-(4-oxo-4H-chromen-3-yl)-meth-(E)-ylidene]-hydrazide with Cu (II) (11).
Green solid. Yield: 65%. m.p. > 300 ◦C. Anal. calcd. for C17H11ClCuFN2O3: C, 49.88; H, 2.69; N,
6.85. Found: C, 50.07; H, 3.07, N: 6.32%. FT IR (KBr, cm−1) νmax: 1636.91 (C=O), 1573.46 (CH=N),
1239.25 (C-O), 614.26 (Cu-N). HRMS (ESI) m/z calcd. for C17H12ClCuFN2O3 (M + H)+: 410.9973,
found 411.0966.
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3.5. X-ray Diffraction Studies
Single crystal X-ray data were collected on a micro-focus SuperNova diffractometer (Rigaku
Oxford Diffraction, Yarnton, UK) with an Atlas detector using MoKα andω scan. The measurements
were carried out at low temperature for 1, 8 and 10 whereas at room temperature for 3 and 5. The X-ray
data were corrected for absorption [36]. All structures were solved using SHELXT [37] and refined
with SHELXL-2014/7 [38]. The crystallographic programs PLATON [39] and MERCURY [40] were
used for structure analysis and presentation of the results. Crystallographic data and the final figures
of merit for structure refinements are summarized in Table 1. Crystallographic data for the structural
analyses of 1, 3, 5, 8 and 10 have been deposited with the Cambridge Crystallographic Data Centre
(CCDC nos.1851685–1851689). These data can be obtained free of charge via http://www.ccdc.
cam.ac.uk/conts/retrieving.html (or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK;
Fax: +44-1223-336-033; E-mail: deposit@ccdc.cam.ac.uk).
3.6. Research on Antimicrobial Potential (Initial Determination)
The microbial reference strains representing different families of bacteria and fungi, pathogenic for
man and animals, were used. The 15 strains were derived from international microbial collections held
by the Department of Pharmaceutical Microbiology and Microbiological Diagnostics of the Medical
University of Lodz: Candida albicans ATCC 10231, Enterococcus faecalis ATCC 29212, Klebsiella pneumoniae
ATCC 700603, Pseudomonas aeruginosa NCTC 6749, Proteus vulgaris CCM 1799, Staphylococcus epidermidis
ATCC 12228, Shigella flexneri ATCC 12022, Streptococcus pneumoniae ATCC 49619, Streptococcus pyogenes
ATCC 19615, Corynebacterium jeikeium K411, Escherichia coli ATCC 25922, Staphylococcus aureus NCTC
4135, Streptococcus dysgalactiae subsp. equisimilis ATCC 12394, Neisseria meningitidis DSM 25942, Listeria
monocytogenes PCM 2191.
The strains were stored at −80 ◦C, frozen in a 1:1 mixture of Brain Heart Infusion (BHI) broth
and glycerol. The reference strains, depending on the growth requirements, were grown on a solid
medium—nutrient agar, nutrient agar with 5% addition of lambs defibrinated blood or (in the case
of Corynebacterium jeikeium) Triptic Soy Agar (TSA) with the addition of sheep blood, yeast extract
and Tween-80. The susceptibility of the strains to chemical compounds was measured analogously
to the adopted method of diffusion and disc preparation of antibiotics for compounds introduced
into treatment [41]. After receiving the pure culture of the reference strain, obtained from frozen
samples and grown on the appropriate medium for growth requirements, suspensions of the tested
strains were prepared in a physiological NaCl solution with a density of 0.5 on the McFarland scale.
These suspensions were seeded with a cotton ball over the entire surface of the test medium. Discs
impregnated with the test compound at a concentration of 100 or 200 µg/mL were then placed on it
and incubated for 24 h at 37 ◦C.
3.7. XTT-Assay—Cell Culture
The mouse fibroblast cell line L929 (Sigma-Aldrich) was grown in MEM (Minimum Essential
Medium) (Biowest, Nuaillé, France) containing 10% of Fetal Bovine Serum (Biowest), 1 mmol/L
sodium pyruvate (Biological Industries, Cromwell, CT, USA), 0.5 mmol/L non-essential amino acids
(Sigma-Aldrich) and 100 units/mL penicillin with 100 mg/mL streptomycin (Biological Industries)
in an incubator at 37 ◦C with 5% CO2. Cells were plated and grown to 80% confluence before the
initiation of the assay.
The EA.hy926 cell line (the human umbilical vein, somatic cell hybrid, American Type Culture
Collection, Manassas, VA, USA) was used to evaluate the cytotoxicity of novel compounds. Cells
were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) which contains 10% of Fetal Bovine
Serum (Biowest), 2 mmol/L glutamine (Sigma-Aldrich) and 100 units/mL penicillin with 100 mg/mL
streptomycin (Biological Industries). Cells were plated and grown in an incubator at 37 ◦C with 5%
CO2 to 80% confluence before the initiation of the assay.
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3.8. XTT Cytotoxicity Assay
The XTT assay was used to evaluate cell metabolic activity [42,43]. In viable cells,
2,3-bis-(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxanilide (XTT) is metabolically
reduced to a water-soluble orange formazan product. The number of viable cells is correlated with
the colour intensity determined by photometric measurements. XTT (Serva, Heidelberg, Germany)
was dissolved in MEM without phenol red (PAN-Biotech, Aidenbach, Germany) or DMEM without
phenol red (PAN-Biotech) at a concentration of 1 mg/mL. Phenazine metosulphate (PMS) (Serva) was
dissolved in phosphate-buffered saline (PBS, 5 mmol/L). PMS solution was then added to the XTT
solution at a concentration of 25 µM. Investigated compounds were dissolved in dimethyl sulfoxide
(DMSO) to obtain stock solutions.
L929 and EA.hy926 cells were seeded into 96-well plates at a density of 1 × 104 cells per well.
They were cultured for 24 h in the incubator (37 ◦C and 5% CO2). After that time, the medium
was removed. Then the 100 µL of medium containing investigated compounds (in the range of
concentration 0.01–1250 µmol/L) or only culture medium (blank control) were added. Cisplatin was
used as a reference compound. Cells were further incubated for 24 h. At the third day, the old medium
were removed and cells were washed with PBS. 100 µL of culture medium with the additional 50 µL
of the XTT/PMS solution were added to each well. Plates were incubated in the dark for 3 h at
37 ◦C. Then, the plates were swayed and an aliquot of 100 µL from each well was transferred into the
corresponding well of a new plate. Finally, the absorbance was measured by using the microplate
reader (Synergy H1, BioTek, Winooski, VT, USA) at a wavelength of 450 nm. The cell viability was
expressed as a percentage of the control values (blanks).
3.9. Statistical Analysis of Cell Proliferation
All statistical analyses were performed using Statistica (version 13.1.336.0 PL, DELL Inc.,
Tulsa, OK, USA) software [44]. The data was analysed using the t-test and the Shapiro-Wilk test.
The significance levels were set at p < 0.05 for the t-test and p > 0.05 for the Shapiro-Wilk test.
4. Conclusions
The presented method for synthesizing hydrazine or hydrazide derivatives of 3-formylchromone
with fluorine substituents resulted in the creation of novel ligands which can be used to synthesize the
respective complexes with metal ions. Eight hydrazine and two hydrazide derivatives of chromone
with fluorine substituents were obtained as a result of chemical condensation of 3-formylchromone
with respective hydrazines or hydrazide. X-ray single-crystal studies confirmed that in all structures,
the hydrazine moiety is oriented similarly with respect to the chromone ring. The bond lengths
and angles were found to be in good agreement to each other. The crystal packing appeared to be
dominated by N-H···O interactions, with hydrogen-bonded dimers being the preferred structural
motif. The reaction of the ligand with copper (II) chloride resulted in neutral mononuclear complex.
All compounds described in this paper were initially tested for antimicrobial properties, and 1, 4,
7, 9, 10, 11 were found to exhibit antimicrobial potential. Tested compounds were able to inhibit
specific microbial growth during the experiment. A good number of synthesized compounds exhibited
comparable or higher antiproliferative activities than the control drug cisplatin. 5 and 11 were found to
possess IC50 values below 1 µmol/L on EA.hy926 cell line. This supports the hypothesis that hydrazide
derivatives of 3-formylchromone constitute a class of potential antiproliferative agents.
Supplementary Materials: The following are available online. Table S1: Selected geometric parameters (Å,◦) for
1, 3, 5, 8 and 10. Table S2: Aromatic pi· · ·pi interactions (Å,◦) for structures 1, 5, 8, 10. Figure S3: Cell proliferation
study concentration-response curves for tested compounds on cell lines: L929 EA.hy926. Figure S4: 1H-NMR and
13C-NMR Spectra.
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